Shortly after the U.S. FDA label expansion, the Committee for Medicinal Products for Human Use recommended the approval of olaparib for patients in the European Union (EU) as a monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with gBRCA mutations who have HER2- high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy [13]. The gene discussed is ERBB2; the disease is breast carcinoma.